Summary The effect of the 06-alkylguanine-DNA alkyltransferase (AGT) inhibitor, 06-benzylguanine (06_ BG), on the anti-tumour activity of 8-carbamoyl-3-methylimidazo[5,1-d] 
The prognosis for patients with glioblastoma is particularly poor, given that malignant brain tumours commonly exhibit intrinsic or acquired resistance to chemotherapy (De Vita, 1989) . Conventional treatment for malignant glioma includes the chloroethylating agent BCNU, which may produce transient responses, but does little to improve long-term survival (Steward, 1989) . Temozolomide, a methylating imidazotetrazinone, has recently been found to have greater activity than BCNU in a number of human brain tumour xenografts (Friedman et al., 1995) and promising clinical activity against glioblastoma during phase I and II evaluation (Newlands et al., 1992; O'Reilly et al., 1993) . Nevertheless, the DNA repair protein AGT, which mediates resistance to BCNU, can also limit the efficacy of temozolomide (Catapano et al., 1987) . Although the cytotoxicity of BCNU and temozolomide can be attributed to quite different DNA lesions, both depend upon initial adduct formation at the o6-position of guanine (Tong et al., 1982; Tisdale, 1987) . o6-guanine adducts in DNA are removed by AGT in a stoichiometric reaction, which renders the cytoprotective protein irreversibly inactive (Pegg, 1990) . Since cellular AGT activity can be restored only by de novo protein synthesis, its depletion, with a potent inhibitor such as o6-BG, has been proposed as a useful adjuvant to methylating or chloroethylating treatment. 06-BG has indeed been found to enhance the activity of BCNU in many preclinical models (Dolan et al., 1991; Friedman et al., 1992; Mitchell et al., 1992; Gerson et al., 1993) , and recent studies suggest that temozolomide can also benefit from 06-BG pretreatment (Friedman et al., 1995; Wedge et al., 1996) . However, it is generally accepted that the potentiation of methylation or chloroethylation by 06-BG is proportional to AGT activity, with no appreciable enhancement of activity in tissues with low AGT (i.e. < 15 fmol mg-' protein) (Gerson et al., 1988; Dolan et al., 1991; Plowman et al., 1994) . In contrast, this paper indicates that the activity of both temozolomide and BCNU can be significantly increased by 06-BG pretreatment, in a human glioma xenograft with an AGT activity of < 6 fmol mg-1 protein. 
Treatment
Tumour volumes were calculated using the formula for a prolate ellipsoid (Geran et al., 1972) 
Results
U87MG xenografts used in this study were established from tumours which had been serially passaged seven times previously. The AGT activity of these xenografts was 4.3 + 1.5 fmol mg-' protein (n =5, mean + s.d.), which was similar to that of newly established tumours (3.0+0.4 fmol mg-' protein). AGT activity remained undetectable for at least 5 h following the administration of 40 mg kg-' 06-BG, but was determined to be 0.9 + 0.2 fmol mg-' protein 24 h after O-BG treatment. O-BG was administered at the maximum dose which could be given without inducing any weight loss or mortality (40 mg kg-1). In contrast, the anti-tumour responses produced by treatment with temozolomide or BCNU alone were obtained at only a fraction of the maximum tolerated doses of 300 mg kg-' and 30 mg kg-respectively (data not shown).
Tumour growth was not inhibited by the administration of O-BG (40 mg kg-') with either vehicle solution (Tables I  and II) . However, when 06-BG was administered before 5 or 10 mg kg-' temozolomide, a statistically significant (P<0.002) increase in tumour growth delay was observed of approximately 10 days (Figure 1 , Table I ). The growth delay produced by 10 mg kg-1 temozolomide with 06-BG, was equivalent to that produced by a 3.5-fold greater dose of temozolomide alone (Table I) . No loss of body weight was observed with temozolomide alone or in combination with O-BG, and weight increases were similar to those of control animals receiving only vehicle solutions.
O-BG also increased tumour responses when administered before BCNU (Figure 2 , Table II (Table II) suggests that the enhancement of BCNU anti-tumour activity by O6-BG was between 2.5-and 4-fold. Although no loss in body weight was produced by 10 mg kg-' BCNU alone, weight losses were observed when 06-BG was administered before 4 mg kg-' BCNU with a nadir of -6.0+1.2% (mean+s.d.).
Discussion
The use of 06-BG as a therapeutic adjuvant to methylating or chloroethylating chemotherapy may be particularly applicable to the clinical treatment of glioblastoma, since AGT is frequently elevated in tumorigenesis of the brain (Silber et al., 1993; Wiestler et al., 1984) .
Although 06-BG has been shown to clearly enhance the activity of BCNU in a number of human xenograft models (Friedman et al., 1992; Felker et al., 1993; Sarker et al., 1993; Dolan et al., 1994) , moderate enhancement of temozolomide activity has previously been demonstrated only once in vivo; in a medulloblastoma xenograft with an AGT activity of 94.0 + 30.3 fmol mg-' protein (Friedman et al., 1985) . An additional study investigating a temozolomide and 06-BG combination suggested that no enhancement of activity could be obtained in a glioblastoma xenograft with an AGT activity of 7.4 + 3.7 fmol mg-' protein (Plowman et al., 1994) . Both of these results correlate with xenograft studies examining BCNU and O6-BG, which indicate that sensitisation by 06-BG is greatest in tumours with most AGT The enhancement of temozolomide and BCNU activity observed in this study is therefore particularly surprising, as the U87MG xenograft had similar AGT activity to that of the U87MG cell line in vitro (Wedge et al., 1996) . These antitumour results are however, corroborated by one other experiment in which 06-BG increased the anti-tumour activity of BCNU in a glioma xenograft with no detectable AGT activity (Felker et al., 1993) . That temozolomide and BCNU activity can be enhanced by 06-BG in vivo, without any corresponding potentiation in vitro, may suggest that some efficacy is derived from a pharmacokinetic interaction with 06-BG. These data also suggest that clinical combinations of 06-BG with methylating or chloroethylating chemotherapy will result in a greater incidence of toxicity and/or secondary malignancy (Yarosh, 1985) in normal tissues with low AGT activity. Nevertheless, 06-BG may still afford a useful increase in the therapeutic index of temozolomide and BCNU where AGT-mediated tumour resistance is apparent (Mitchell et al., 1992; Felker et al., 1993; Gerson et al., 1993) . Although the activities of temozolomide or BCNU in the U87MG xenograft were enhanced to a similar extent by o6_ BG, it has been suggested that the U87MG tumour cell line exhibits additional resistance to chloroethylation that is unrelated to AGT activity (Wedge et al., 1996) . In addition, single dosing schedules with 06-BG in vitro indicate that BCNU is potentiated to a greater extent than is temozolomide (Wedge et al., 1996) . However, temozolomide is significantly less toxic than BCNU and demonstrates highly schedule-dependent anti-tumour activity (Stevens et al., 1987) . Multiple dosing regimens, amenable to methylating but not chloroethylating treatment, may therefore offer a substantial therapeutic advantage. Indeed, the potentiation of temozolomide cytotoxicity by 06-BG in vitro has been found to increase linearly with repeat dosing on five consecutive days (Wedge et al., 1996) . A combination of temozolomide and 06-BG should therefore be considered for clinical development, particularly for the treatment of central nervous system tumours which may be more responsive to temozolomide than BCNU (Friedman et al., 1995) . 
